Life-Changing Medicines.
Redefining Possibilities.
patient story
Life After AML
When Norman was diagnosed with an aggressive form of acute myeloid leukemia (AML), doctors told him the odds were against him. When it came time for a bone marrow transplant, no donors could be found. Then a woman in Germany, who signed up for the registry two days prior, emerged as a match.
Norman’s Story
Our science
Innovation That Performs
In the treatment of cancer, one size does not fit all. At Jazz, our researchers are committed to discovering new possibilities for delivering innovative treatments as effectively and safely as possible.
Learn More
News and Events
September 18, 2019
Jazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update
August 27, 2019
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
August 12, 2019
Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.
Jazz strives to create a workplace culture that supports a diverse, multicultural workforce and provides an inclusive environment where all employees are empowered to contribute and succeed.
See all News
Jazz Pipeline
PRE-CLINICAL
Oxybate
Once Nightly Formulation

CombiPlex
Solid tumors candidate

CombiPlex
Hem/Onc exploratory activities

Recombinant Crisantaspase-HLE2
ALL/other hematological malignancies

Recombinant Pegaspargase1
Hematological malignancies

Defibrotide
Exploratory activities

Exosome NRAS candidate2
Hematological malignancies

Exosome STAT3 candidate2
Hematological malignancies

Exosome-based candidates2
Solid tumors/ Hematological malignancies

Pan-RAF Inhibitor Program
RAF & RAS mutant tumors

PHASE 1
CPX-351 + gemtuzumab3
R/R AML or HMA Failure
MDS

CPX-351 + venetoclax
Low Intensity Therapy for first-line, unfit AML (Phase 1b)

CPX-3513
Low Intensity Dosing for higher risk MDS

IMGN6321
CD123+ Hematological malignancies5

PHASE 2
Defibrotide
Prevention of aGvHD

Defibrotide4
Treatment of TA-TMA

Defibrotide4
Prevention of CAR-T associated neurotoxicity

CPX-351 + venetoclax3
de novo or R/R AML

CPX-3516
HR-MDS

CPX-3516
R/R AML (COG)

CPX-3514,6
Newly diagnosed older adults with HR-AML

CPX-351 + venetoclax4,6
HR-AML

JZP-458 (Recombinant Crisantaspase)4
ALL (Phase 2/3)

CX-8998
Essential Tremor

PHASE 3
JZP-258
Cataplexy & EDS in narcolepsy

JZP-258
Idiopathic hypersomnia

Defibrotide
Prevention of VOD

CPX-3516
AML or HR-MDS (AML19)

CPX-3516
AML or HR-MDS (AML18)

CPX-3516
Newly diagnosed adults with standard- and HR-AML

CPX-3514,6
Newly diagnosed pediatric patients

REGULATORY
Solriamfetol EU
EDS in OSA and Narcolepsy

Sleep / Neuroscience
Hematology / Oncology
1Opt-in opportunity
2Partnered collaboration
3Jazz & MD Anderson Cancer Center collaboration study
4Planned
5Including AML and BPDCN
6Cooperative group study

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
More About Jazz
Living Our Values

Careers at Jazz

Clinical Trials

Learn More

By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.
Our Medicines